165 related articles for article (PubMed ID: 20167564)
1. [Hepatotoxicity of metastatic colorectal cancer chemotherapy: systematic review].
Baumgaertner I; Ratziu V; Vaillant JC; Hannoun L; Poynard T; André T
Bull Cancer; 2010 May; 97(5):559-69. PubMed ID: 20167564
[TBL] [Abstract][Full Text] [Related]
2. Consequences of chemotherapy on resection of colorectal liver metastases.
Pessaux P; Chenard MP; Bachellier P; Jaeck D
J Visc Surg; 2010 Aug; 147(4):e193-201. PubMed ID: 20655821
[TBL] [Abstract][Full Text] [Related]
3. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases.
Khan AZ; Morris-Stiff G; Makuuchi M
J Hepatobiliary Pancreat Surg; 2009; 16(2):137-44. PubMed ID: 19093069
[TBL] [Abstract][Full Text] [Related]
4. Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection.
Duwe G; Knitter S; Pesthy S; Beierle AS; Bahra M; Schmelzle M; Schmuck RB; Lohneis P; Raschzok N; Öllinger R; Sinn M; Struecker B; Sauer IM; Pratschke J; Andreou A
Eur J Surg Oncol; 2017 Sep; 43(9):1668-1681. PubMed ID: 28599872
[TBL] [Abstract][Full Text] [Related]
5. Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases.
Morris-Stiff G; Tan YM; Vauthey JN
Eur J Surg Oncol; 2008 Jun; 34(6):609-14. PubMed ID: 17764887
[TBL] [Abstract][Full Text] [Related]
6. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival.
Viganò L; Capussotti L; De Rosa G; De Saussure WO; Mentha G; Rubbia-Brandt L
Ann Surg; 2013 Nov; 258(5):731-40; discussion 741-2. PubMed ID: 24045448
[TBL] [Abstract][Full Text] [Related]
7. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience.
Wolf PS; Park JO; Bao F; Allen PJ; DeMatteo RP; Fong Y; Jarnagin WR; Kingham TP; Gönen M; Kemeny N; Shia J; D'Angelica MI
J Am Coll Surg; 2013 Jan; 216(1):41-9. PubMed ID: 23041049
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab improves splenomegaly and decreases production of hyaluronic acid after L-OHP based chemotherapy.
Arakawa Y; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T; Hanaoka J; Kanamoto M; Iwahashi S; Saito Y; Yamada S; Asanoma M; Takasu C; Bando Y
Anticancer Res; 2014 Apr; 34(4):1953-8. PubMed ID: 24692731
[TBL] [Abstract][Full Text] [Related]
9. [Influence of pre-surgical chemotherapy on liver parenchyma and post-surgical outcome of patients subjected to hepatectomy due to colorectal carcinoma metastases].
Gómez-Ramírez J; Martín-Pérez E; Amat CG; Sanz IG; Bermejo E; Rodríguez A; Larrañaga E
Cir Esp; 2010 Dec; 88(6):404-12. PubMed ID: 20971458
[TBL] [Abstract][Full Text] [Related]
10. Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis.
Chaudhury P; Hassanain M; Bouganim N; Salman A; Kavan P; Metrakos P
HPB (Oxford); 2010 Feb; 12(1):37-42. PubMed ID: 20495643
[TBL] [Abstract][Full Text] [Related]
11. Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer.
Saif MW
World J Gastroenterol; 2009 Aug; 15(31):3855-64. PubMed ID: 19701965
[TBL] [Abstract][Full Text] [Related]
12. [Hepatic resection after systemic chemotherapy for liver metastasis of colorectal cancer].
Nishigaki T; Ide Y; Murata K
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2566-8. PubMed ID: 21224641
[TBL] [Abstract][Full Text] [Related]
13. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis.
Rubbia-Brandt L; Lauwers GY; Wang H; Majno PE; Tanabe K; Zhu AX; Brezault C; Soubrane O; Abdalla EK; Vauthey JN; Mentha G; Terris B
Histopathology; 2010 Mar; 56(4):430-9. PubMed ID: 20459550
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
Klinger M; Eipeldauer S; Hacker S; Herberger B; Tamandl D; Dorfmeister M; Koelblinger C; Gruenberger B; Gruenberger T
Eur J Surg Oncol; 2009 May; 35(5):515-20. PubMed ID: 19200687
[TBL] [Abstract][Full Text] [Related]
15. Sinusoidal obstruction syndrome is a major feature of hepatic lesions associated with oxaliplatin neoadjuvant chemotherapy for liver colorectal metastases.
Rubbia-Brandt L; Mentha G; Terris B
J Am Coll Surg; 2006 Jan; 202(1):199-200. PubMed ID: 16377516
[No Abstract] [Full Text] [Related]
16. [Systemic therapy for colorectal cancer].
Pestalozzi BC; Jäger D; Knuth A
Chirurg; 2005 Jun; 76(6):570-2, 574. PubMed ID: 15905968
[TBL] [Abstract][Full Text] [Related]
17. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
Martin RC; Scoggins CR; Schreeder M; Rilling WS; Laing CJ; Tatum CM; Kelly LR; Garcia-Monaco RD; Sharma VR; Crocenzi TS; Strasberg SM
Cancer; 2015 Oct; 121(20):3649-58. PubMed ID: 26149602
[TBL] [Abstract][Full Text] [Related]
18. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
Fernandez FG; Ritter J; Goodwin JW; Linehan DC; Hawkins WG; Strasberg SM
J Am Coll Surg; 2005 Jun; 200(6):845-53. PubMed ID: 15922194
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.
Larsen FO; Pfeiffer P; Nielsen D; Skougaard K; Qvortrup C; Vistisen K; Fromm AL; Jørgensen TL; Bjerregaard JK; Hoegdall E; Jensen BV
Acta Oncol; 2011 May; 50(4):574-7. PubMed ID: 21529301
[TBL] [Abstract][Full Text] [Related]
20. [Chemotherapy's hepatotoxicity: what is the impact on surgery?].
Pessaux P
J Chir (Paris); 2010 Jan; 147 Suppl 1():S7-S11. PubMed ID: 20172202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
